9 May 2020 - Today, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced the allocation plan for the drug remdesivir. 

The allocation is from a donation by Gilead to the United States which was finalised on 3 May 2020. 

The donated doses of the treatment, which received an Emergency Use Authorization from the U.S. FDA, will be used to treat hospitalised COVID-19 patients in areas of the country hardest hit by the pandemic.

Read US Department of Health and Human Services press release